Key result
Ranolazine linked to ~120% increased myocardial perfusion and reduced angina in a microvascular dysfunction case.
Why the study?
Women with signs and symptoms of ischemia often have persistent symptoms and a high prevalence of microvascular coronary dysfunction without obstructive coronary artery disease.
Does ranolazine improve symptoms and myocardial perfusion in a patient with microvascular coronary dysfunction?
Case Report (n=1)
No
Does ranolazine improve symptoms and myocardial perfusion in a patient with microvascular coronary dysfunction?
Ranolazine may be an effective treatment for improving symptoms and myocardial perfusion in patients with microvascular coronary dysfunction and no obstructive coronary artery disease.
Answers are grounded in this paper and cite their sources.
May support microvascular evaluation in young women with refractory angina and normal arteries; leaves open whether this alters prognosis or treatment.
Women often exhibit persistent symptoms, functional disability and a relatively high prevalence of microvascular coronary dysfunction (MCD) with no obstructive coronary artery disease (CAD) when evaluated for signs and symptoms of myocardial ischemia. A 27-year-old woman was referred by her treating cardiologist for symptoms of persistent chest pain for 10 years. Cardiac catheterization showed normal coronary arteries. Given the constellation of persistent chest pain and no obstructive CAD, a diagnosis of MCD was suspected, and she underwent coronary reactivity testing (CRT) with intracoronary infusions of adenosine, acetylcholine and nitroglycerin to test nonendothelial- and endothelial-dependent, micro- and macro-vascular coronary function. CRT results were consistent with a diagnosis of MCD. The patient was started on ranolazine, with significant improvement in symptoms. Cardiac magnetic resonance imaging (CMRI) after 3 months of treatment demonstrated improvement in perfusion compared to baseline. J Med Cases. 2014;5(1):23-25 doi: http://dx.doi.org/10.4021/jmc1522w
No takes yet. Share an insight, caveat, or question.
Mian (2014) conducted a case report in Microvascular coronary dysfunction (n=1). Ranolazine vs. Baseline was evaluated on Angina severity and myocardial perfusion. Treatment with ranolazine for 3 months in a woman with microvascular coronary dysfunction improved angina severity from 9/10 to 5/10 and increased myocardial perfusion reserve index from 1.5 to 3.3.
Synapse has enriched 10 related papers. Consider them for comparative context: